WallStreetZenWallStreetZen

NASDAQ: XFOR
X4 Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for XFOR

Based on 3 analysts offering 12 month price targets for X4 Pharmaceuticals Inc.
Min Forecast
$7.00+236.54%
Avg Forecast
$8.50+308.65%
Max Forecast
$10.00+380.77%

Should I buy or sell XFOR stock?

Based on 3 analysts offering ratings for X4 Pharmaceuticals Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their XFOR stock forecasts and price targets.

XFOR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
B. Riley Securities
Top 1%
100
Strong BuyMaintains$7.00+236.54%2022-05-19
HC Wainwright & Co.
Bottom 10%
10
BuyMaintains$8.50+308.65%2022-05-13
Canaccord Genuity
Top 28%
73
Strong BuyMaintains$10.00+380.77%2022-04-05

1 of 1

Forecast return on equity

Is XFOR forecast to generate an efficient return?
Company
-52.5%
Industry
22.46%
Market
122.06%
XFOR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is XFOR forecast to generate an efficient return on assets?
Company
-19.49%
Industry
13.57%
XFOR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

XFOR earnings per share forecast

What is XFOR's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$1.70
Avg 2 year Forecast
-$1.07
Avg 3 year Forecast
-$0.64

XFOR revenue forecast

What is XFOR's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$3.4M
Avg 2 year Forecast
$19.6M
Avg 3 year Forecast
$41.0M

XFOR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
XFOR$2.08$8.50+308.65%Strong Buy
ALZN$1.48$11.50+677.03%Strong Buy
MREO$0.97$4.50+366.32%Strong Buy
IMMP$1.70$8.15+379.41%Strong Buy
NBTX$4.01$8.50+111.81%Strong Buy

X4 Pharmaceuticals Stock Forecast FAQ

Is X4 Pharmaceuticals Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: XFOR) stock is to Strong Buy XFOR stock.

Out of 3 analysts, 2 (66.67%) are recommending XFOR as a Strong Buy, 1 (33.33%) are recommending XFOR as a Buy, 0 (0%) are recommending XFOR as a Hold, 0 (0%) are recommending XFOR as a Sell, and 0 (0%) are recommending XFOR as a Strong Sell.

If you're new to stock investing, here's how to buy X4 Pharmaceuticals stock.

What is XFOR's earnings growth forecast for 2022-2024?

(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

X4 Pharmaceuticals's earnings in 2022 is -$101,522,000.On average, 4 Wall Street analysts forecast XFOR's earnings for 2022 to be -$116,698,316, with the lowest XFOR earnings forecast at -$157,885,956, and the highest XFOR earnings forecast at -$96,790,956. On average, 5 Wall Street analysts forecast XFOR's earnings for 2023 to be -$73,451,293, with the lowest XFOR earnings forecast at -$86,494,046, and the highest XFOR earnings forecast at -$58,349,158.

In 2024, XFOR is forecast to generate -$43,933,484 in earnings, with the lowest earnings forecast at -$64,527,304 and the highest earnings forecast at -$27,458,427.

What is XFOR's revenue growth forecast for 2022-2024?

(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.53%.

X4 Pharmaceuticals's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast XFOR's revenue for 2022 to be $234,083,092, with the lowest XFOR revenue forecast at $234,083,092, and the highest XFOR revenue forecast at $234,083,092. On average, 2 Wall Street analysts forecast XFOR's revenue for 2023 to be $1,343,746,781, with the lowest XFOR revenue forecast at $257,422,755, and the highest XFOR revenue forecast at $2,430,070,807.

In 2024, XFOR is forecast to generate $2,814,488,788 in revenue, with the lowest revenue forecast at $634,289,668 and the highest revenue forecast at $4,489,452,847.

What is XFOR's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: XFOR) forecast ROA is -19.49%, which is lower than the forecast US Biotechnology industry average of 13.57%.

What is XFOR's Price Target?

According to 3 Wall Street analysts that have issued a 1 year XFOR price target, the average XFOR price target is $8.50, with the highest XFOR stock price forecast at $10.00 and the lowest XFOR stock price forecast at $7.00.

On average, Wall Street analysts predict that X4 Pharmaceuticals's share price could reach $8.50 by May 19, 2023. The average X4 Pharmaceuticals stock price prediction forecasts a potential upside of 308.65% from the current XFOR share price of $2.08.

What is XFOR's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: XFOR) X4 Pharmaceuticals's current Earnings Per Share (EPS) is -$3.36. On average, analysts forecast that XFOR's EPS will be -$1.70 for 2022, with the lowest EPS forecast at -$2.30, and the highest EPS forecast at -$1.41. On average, analysts forecast that XFOR's EPS will be -$1.07 for 2023, with the lowest EPS forecast at -$1.26, and the highest EPS forecast at -$0.85. In 2024, XFOR's EPS is forecast to hit -$0.64 (min: -$0.94, max: -$0.40).

What is XFOR's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: XFOR) forecast ROE is -52.5%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.